Mycovia Pharmaceuticals Announces Presentation of Oteseconazole (VT-1161) Phase 3 Data Demonstrating Safety and Efficacy for Treatment of Recurrent Vulvovaginal Candidiasis (RVVC) at the 2021 IDSOG Annual Meeting
DURHAM, N.C.–(BUSINESS WIRE)–Mycovia Pharmaceuticals, Inc. (Mycovia), an emerging biopharmaceutical company dedicated to recognizing and empowering…